Pimitespib achieved stable disease in 66.7% of patients with advanced GISTs in an expanded access program in Japan. Approved as a fourth-line treatment, pimitespib extended progression-free survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback